LungArchives
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lung 1 min.
Limertinib is a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This study aimed to prospectively assess the efficacy and safety of limertinib versus gefitinib as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with...
The lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study
Lung 4 min.
Advanced non-small-cell lung cancer (NSCLC) is a formidable malignancy associated with a poor prognostic outlook, typically manifesting with notably low 1-year and 5-year overall survival rates [1]. Advanced NSCLC often loses the opportunity for curative surgery at the time of diagnosis [2]. Recently,...
Early detection of non-small cell lung cancer: an electronic health record data-driven approach
Lung 7 min.
Cancer is the second leading cause of death in the USA, after heart disease [1], and late diagnosis contributes significantly to poor survival, particularly in cancers like lung and pancreatic where over half of cases present at a metastatic stage [2]. In 2024, an estimated 234,580 new lung cancer cases...
Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy
Lung 4 min.
Non-small cell lung cancer (NSCLC) continues to be a major contributor to cancer-related deaths globally. Although systemic treatments such as chemotherapy and targeted therapies have advanced considerably, the outlook for individuals with advanced-stage NSCLC remains unfavorable. The introduction of...
